Share this page!

Albert Vilella Profile picture
Twitter logo
11 Jan, 5 tweets, 4 min read
#JPM2021 @10xGenomics My Highlights:
Fixed RNA: does this mean less ambient RNA, higher efficiency even if the original sample is fresh? Image
#ChromiumX 1M cells per run experiment. No word on price per bead compared to Chromium NextGEM. Image
#Visium for #FFPE: similar sensitivity than fresh frozen (#FF) Image
#Visium #CytAssist "slide in, visium prep out". Compatible with #FFPE. (if decent for "old FFPE" samples, then Big Pharma will love this: going back to their shelves of FFPE and processing them). Image
#VisiumHD from 4x to 1500x resolution. (How does this compare to other players / recent acquisition tech? @LGMartelotto @coregenomics) Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Albert Vilella

Albert Vilella Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AlbertVilella

Albert Vilella Profile picture
14 Jan
Some stats and facts about the #Takifugu #rubripes assembly by @genomeark: this is the third iteration of the assembly. The first was completed in 2002. There was another iteration done in 2011. Why was the pufferfish sequenced so early? A lot has got to do with Sydney Brenner... Image
Indeed, as we can see in this archived version of @ensembl, the Fugu genome was the 5th vertebrate genome to be completed, after human/mouse/rat and zebrafish. Even though zebrafish is widely used as a model organism, Sydney Brenner argued that Fugu was worth sequencing ... Image
... The reason is that Sydney Brenner was passionate (obsessed?) with gene duplications and functional diversification. I.e. a gene duplicates in two copies, and over time, each copy can specialize in doing something slightly different. ...
Read 8 tweets
Albert Vilella Profile picture
13 Jan
#JPM2021 @TwistBioscience My Highlights: back to the #DNAWrite field. TwistBio chip: 1M oligos but only as centralised factory setting. Image
Expanding to a new factory in Portland (roadmap 2022) to reduce TAT. Also mentioned the "long tail" of Clonal Ready Gene Fragments. Image
They have a few slides on #DNAasStorage with a denser chip in prototype phase where they think they can archive 1Tb for $100 (pay once, archive forever*) which, if my calculations are correct, would allow for 10-12 years of @awscloud Deep Glacier or similar mth/GB=0.00099*12*1E3 Image
Read 5 tweets
Albert Vilella Profile picture
13 Jan
#JPM2021 #LiquidBiopsy notable by their absence, which is more than excusable in these pandemic times: @freenome, Biocartis, Biodesix, Epic Sciences, ArcherDx (not by this name anyway). Worth following developments for them. In my book, worth following #Freenome of the ones here.
Smaller #LiquidBiopsy #Oncology #Diagnostics players also not at #JPM2021 but important in the field: Personalis, Inivata, Exosome Diagnostics, Epigenomics Ag, Personal Genome Diagnostics, Foundation Medicine, Singlera, Cambridge Epigenetix, and Bluestar Genomics.
Now added #BiologicalDynamics to my #LiquidBiopsy list crunchbase.com/organization/b… which displace #Biocept in the #Top30 bit.ly/liqbiop (thanks Kevin Han for the follow).
Read 5 tweets
Albert Vilella Profile picture
13 Jan
#JPM2021 #AdaptiveBiotech My Highlights: my interest lies in their angle on #LiquidBiopsy for #EarlyCancerDiagnostics, but they also deal with Life Science Research and Drug Discovery. Image
Their T-Detect method is aiming at #MRD monitoring, here shown in a slide that relates it to their ImmunoSEQ T-MAP Cancer mapping tool, and their Identification of clinical TCR candidates. Image
They stress the T-cell Diagnostics angle in different slides. I recall only @freenome explicitly mentioning immune-profiling from the group of companies in early cancer diagnostics and #epigenomics profiling (Grail/GH/Thrive/Freenome/BioStar/CEGX/etc.) Image
Read 5 tweets
Albert Vilella Profile picture
13 Jan
#JPM2021 @carisls My Highlights: in the #CancerDiagnostics area, they position themselves favorably wrt Foundation medicine, Tempus, and Personalis (haven't heard of NEO before). Image
They put #LiquidBiopsy at the end of this trajectory slide: (couldn't see any years in milestones for this) Image
No indication that #Caris are pursuing #Epigenomics profiling of #LiquidBiopsy: they mention exome and transcriptome in their slides. Image
Read 4 tweets
Albert Vilella Profile picture
11 Jan
#JPM2021 #GinkgoBioworks #DNAWrite My Highlights: A comparison of the Moore's Law for #DNASequencing compared to #DNAWrite (still looks Moore's or worse to me) Image
Supported #ModeRNA for #COVID19 vaccine development: Image
#COVID19 #RNAVaccines Image
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @AlbertVilella has new unrolls!

Check out other threads from @AlbertVilella!

Read all threads by @AlbertVilella